On the restricted mean survival time curve in survival analysis

Alternatives to Hazard Ratios for Comparing the Efficacy or Safety of Therapies in Noninferiority Studies

(2015) Hajime Uno et al.   ANNALS OF INTERNAL MEDICINE

Moving Beyond the Hazard Ratio in Quantifying the Between-Group Difference in Survival Analysis

(2014) Hajime Uno et al.   JOURNAL OF CLINICAL ONCOLOGY

Predicting the restricted mean event time with the subject's baseline covariates in survival analysis

(2013) L. Tian et al.   BIOSTATISTICS

Utilizing the integrated difference of two survival functions to quantify the treatment contrast for designing, monitoring, and analyzing a comparative clinical study

(2012) Lihui Zhao et al.   Clinical Trials

The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt

(2011) Patrick Royston et al.   STATISTICS IN MEDICINE

Double Inverse-Weighted Estimation of Cumulative Treatment Effects Under Nonproportional Hazards and Dependent Censoring

(2010) Douglas E. Schaubel et al.   BIOMETRICS

Calibrating parametric subject-specific risk estimation

(2010) T. Cai et al.   BIOMETRIKA

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

(2009) S Vincent Rajkumar et al.   LANCET ONCOLOGY